176 related articles for article (PubMed ID: 7784406)
21. Farnesyltransferase inhibitors and anti-Ras therapy.
Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
[TBL] [Abstract][Full Text] [Related]
22. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells.
Bishop WR; Bond R; Petrin J; Wang L; Patton R; Doll R; Njoroge G; Catino J; Schwartz J; Windsor W
J Biol Chem; 1995 Dec; 270(51):30611-8. PubMed ID: 8530497
[TBL] [Abstract][Full Text] [Related]
23. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
24. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.
James G; Goldstein JL; Brown MS
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4454-8. PubMed ID: 8633088
[TBL] [Abstract][Full Text] [Related]
25. Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
Omer CA; Anthony NJ; Buser-Doepner CA; Burkhardt AL; deSolms SJ; Dinsmore CJ; Gibbs JB; Hartman GD; Koblan KS; Lobell RB; Oliff A; Williams TM; Kohl NE
Biofactors; 1997; 6(3):359-66. PubMed ID: 9288406
[TBL] [Abstract][Full Text] [Related]
26. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox AD; Der CJ; Philips MR
Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
28. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
[TBL] [Abstract][Full Text] [Related]
29. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
Agarwal R; Mohan RR; Ahmad N; Mukhtar H
Mol Carcinog; 1996 Sep; 17(1):13-22. PubMed ID: 8876671
[TBL] [Abstract][Full Text] [Related]
30. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts.
Ura H; Obara T; Shudo R; Itoh A; Tanno S; Fujii T; Nishino N; Kohgo Y
Mol Carcinog; 1998 Feb; 21(2):93-9. PubMed ID: 9496909
[TBL] [Abstract][Full Text] [Related]
31. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
[TBL] [Abstract][Full Text] [Related]
32. Novel anticancer agents move closer to reality.
Travis J
Science; 1993 Jun; 260(5116):1877-8. PubMed ID: 8316828
[No Abstract] [Full Text] [Related]
33. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
34. [Development of farsenyl transferase inhibitors as anticancer agents].
Cestac P; Doisneau-Sixou S; Favre G
Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
[TBL] [Abstract][Full Text] [Related]
35. Farnesyltransferase as a target for anticancer drug design.
Qian Y; Sebti SM; Hamilton AD
Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
[TBL] [Abstract][Full Text] [Related]
37. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Crul M; de Klerk GJ; Beijnen JH; Schellens JH
Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
[TBL] [Abstract][Full Text] [Related]
38. Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes.
Goalstone ML; Draznin B
J Biol Chem; 1996 Nov; 271(44):27585-9. PubMed ID: 8910345
[TBL] [Abstract][Full Text] [Related]
39. v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway.
Laezza C; Di Marzo V; Bifulco M
Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13646-51. PubMed ID: 9811854
[TBL] [Abstract][Full Text] [Related]
40. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Cox AD; Der CJ
Biochim Biophys Acta; 1997 Aug; 1333(1):F51-71. PubMed ID: 9294018
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]